On June 18, 2025, Tivic Health Systems, Inc. announced an Amended and Restated Exclusive License Agreement with Statera Biopharma, replacing an earlier agreement on February 11, 2025; the terms allow for royalty payments in cash or company securities up to $5.6 million.